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A two-month-old girl had severe hypothyroidism and 
was referred to our hospital. She was born at 37 weeks of 
gestation after a normal pregnancy. Her birth weight was 
3200 g. A physical examination indicated that there were 
two purple skin lesions on her left shoulder and right 
groin, and her liver was larger than normal, 4 cm below 
the right costal margin. Abdominal ultrasonography dem-
onstrated multiple hypoechoic lesions throughout the 
liver. No arteriovenous shunt was found. MRI of the he-
patic parenchyma (Fig. 1) confirmed innumerable lesions 
with near-total hepatic parenchymal replacement. No 
other abnormality was evident on physical examination.
Thyroid function examination suggested an elevat-
ed thyroid-stimulating hormone (TSH) of over 150.00 
μIU/mL (Tab. 1), and low free triiodothyronine (FT3) 
was 1.24 pg/mL. Thyroid ultrasonography showed mild 
enlargement of the thyroid. Thyroid-related antibodies 
were negative, and thyroglobulin (TG) was over 500 
ng/mL (normal value 3.5–77 ng/mL).
She started taking levothyroxine 50 mg/d. Two weeks 
later, her TSH level was still over 150 μIU/mL (Tab. 1). 
We thought that the infantile hepatic haemangiomas 
(IHHs) should be treated first. She was requested to take 
oral propranolol (0.5 mg/kg/d) regularly. On the third 
day, the dose of propranolol was increased to 1 mg/kg/d. 
However, her heart rate dropped to 62 bpm. The echocar-
diography showed low left ventricular systolic function 
(Fig. 2AB). Brain natriuretic peptide (BNP) was 20,600 
pg/mL (normal value: 0 ~ 116 pg/mL). She was thought 
to have developed cardiac insufficiency. Oral propranolol 
was suspended, and furosemide and spironolactone were 
given consecutively. However, these treatments did not 
improve the condition. At that time, we noticed that the 
patient’s thyroid function was still abnormal. We increased 
the dose of levothyroxine to 100 μg/d (about 20 μg/kg). 
Her heart rate became normal. Two weeks later, her heart 
ejection fraction improved, and the TSH concentration 
was decreased to a normal level (Tab. 1). She restarted 
propranolol again; it was increased to 2 mg/kg/day in 
about 3–4 weeks. On this occasion she did not have cardiac 
dysfunction. Subsequently she was discharged home.
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Figure 1. Abdominal MRI showing hepatic nodule 
table 1. The results of the patient’s thyroid hormone
Age [months] TSH [μIU/mL] TT4 [μg/dL] TT3 [ng/mL] FT4 [ng/dL] FT3 [pg/mL]
2 > 150,000 7.41 0.38 0.94 1.24
2.6 > 150,000 17.30 0.63 1.42 1.43
3.5 2.34 22.62 0.699 3.78 2.82
4.2 7.901 18.26 0.85 2.21 2.54
8.8 1.740 19.16 1.11 2.58 3.45
Normal value: TSH: 0.87–6.15 μIU/mL; TT4: 6–13.2 μg/dL; TT3: 1.17–2.39 ng/mL; FT4: 0.94–1.44 ng/dL; FT3: 3.3–5.2 pg/mL
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We report a patient with diffuse haemangioma, who 
had severe hypothyroidism and extremely high levels 
of TG. She developed cardiac insufficiency after start-
ing propranolol when her thyroid function still was 
abnormal. Fortunately, adequate doses of levothyroxine 
seemed to be effective for her cardiac insufficiency. 
Cardiac insufficiency may occur in patients with 
IHHs. The causes of cardiac insufficiency are hypo-
thyroidism and arteriovenous shunt [1]. Although our 
patient suffered from cardiac insufficiency, there was no 
evidence to show that she had an arteriovenous shunt. 
Interestingly, her cardiac function improved after re-
ceiving adequate levothyroxine. The T3 is considered as 
a critical regulator of cardiac chronotropic response and 
muscle tone [2], capable of enhancing the sensitivity of 
myocardial β-adrenergic receptors to catecholamines, as 
well as exerting a positive inotropic effect and positive 
chronotropic action to the heart. Thus, hypothyroidism 
with low T3 can lead to bradycardia, and impaired ven-
tricular systolic and diastolic function. Coincidentally, 
a low FT3 level, bradycardia, and impaired ventricular 
were presented in our patient. We reasonably believe 
that the patient’s heart dysfunction was associated with 
hypothyroidism. A low FT3 level was mainly caused by 
type III deiodinase (D3). A hepatic haemangioma can 
secrete a large amount of D3, which causes a rise in 
T4 conversion to rT3 and a decrease in T3 [3]. Adding 
liothyronine may control hypothyroidism and improve 
cardiac insufficiency more rapidly [4]. Levothyroxine 
can reverse cardiac impairment caused by hypothyroid-
ism. A combination of liothyronine and levothyroxine 
may be better in the early treatment stages of cardiac 
insufficiency. Our patient took levothyroxine alone 
because we did not have access to liothyronine, but 
it was still effective to use high-dose LT4. The patient 
started with propranolol 0.5 mg/kg and increased the 
dose rapidly, which may induce the aggravation of 
cardiac dysfunction. We think that the tolerance of 
patients should be fully considered when propranolol 
is used in the treatment of haemangioma. The dosage 
of the drug can be increased more slowly. Using a safe 
maximum dose of levothyroxine early in the treatment 
can help prevent the occurrence of heart failure. 
Both our and Huang’s cases showed that the pa-
tients had high TG levels [4]. It is different from con-
genital hypothyroidism. We speculate that considerably 
more TG-TH may be hydrolysed than normal under the 
stimulation of high TSH concentration. Also, the TG 
released into the blood is more than normal [5], which 
explains why consumptive hypothyroidism patients 
have a high TG level. Based on this fact, TG may be 
conducive to differential diagnosis. 
In conclusion, early in the clinical course of ill-
ness, high-dose thyroid hormone replacement is as 
important as an anti-tumour treatment for these pa-
tients. Propranolol should be initiated at a lower dose of 
0.25 mg/kg/day, and then increased up to 2 mg/kg/day 
after about 3–4 weeks as tolerated. Extremely high TG 
levels can help to distinguish consumptive hypothy-
roidism from congenital hypothyroidism.
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Figure 2. Echocardiograms showing the ejection fraction (EF) change. A. At age 2.1 months; B. At age 2.8 months
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